Safety and Tolerability of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration

Secondary to Age-related Macular Degeneration (AMD) Clinical Trial

Official title: A Phase IV, Long-term, Open-label, Multicenter Extension Study to Evaluate the Safety and Tolerability of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)

Status Completed

Clinical Trial Summary

This extension study will investigate the long-term safety and tolerability of multiple intravitreal injections of ranibizumab administered to patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration who have been previously treated in either of the two ongoing ranibizumab studies CRFB002A2302 (EXCITE) or CRFB002A2303 (SUSTAIN

Clinical Trial Description

n/a

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Choroidal Neovascularization
• Macular Degeneration
• Neoplasm Metastasis
• Neovascularization, Pathologic
• Secondary to Age-related Macular Degeneration (AMD)
• Subfoveal Choroidal Neovascularization (CNV)

• NCT number: NCT00504959
• Study type: Interventional
• Source: Novartis
• Status: Completed
• Phase: Phase 4
• Start date: July 2007
• Completion date: January 2010